ALPA62.19

Alpa Laboratories Limited

· Pharma & Health
₹ CrorePeersBALPHARMAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹131 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity11.0411.387.587.58
Return on Assets9.198.765.835.83
Return on Capital Employed3.991.450.630.63
Return on Invested Capital7.573.182.02-4.38
Margins
EBITDA Margin7.454.233.11-0.99
Operating Margin5.662.271.131.13
Incremental Operating Margin-96.9720.36
Pretax Margin19.0222.8214.954.54
Net Income Margin15.4317.3413.353.16
FCF Margin-2.52-3.846.346.34
Additional
Effective Tax Rate18.8824.0110.6730.47
Sustainable Growth Rate11.0411.387.587.58
Incremental Operating Margin %-96.9720.36-94.37
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.